Sign in
Active, not recruitingPhase 2

A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP

Key facts

Who runs it
Shandong University
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
106 people, planned
Started
21 Aug 2021
Ended
31 Jan 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • dexamethasone
  • diammonium glycyrrhizinate enteric-coated capsule
Record updated
26 January 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Meet the diagnostic criteria for immune thrombocytopenia
  • Untreated hospitalized patients or patients from the clinic, may be male or female, between the ages of 18~ 80 years
  • To show a platelet count <30 * 10\^9/L, or with bleeding manifestations, or both
  • Willing and able to sign written informed consent
  • ITP patients with hepatitis virus infection or ITP patients with abnormal liver function at the time of enrollment, i.e., ITP patients with indications for diammonium glycyrrhizinate enteric-coated capsule, should be separately stratified

Who cannot take part

  • arterial or venous thromboembolism within the 6 months before screening or patients who required anticoagulant treatment
  • an organ or haematopoietic stem-cell transplantation
  • substance misuse within the previous 12 months
  • people who could not adhere to the protocol or were planning to have a surgical procedure in 6 months
  • active or previous malignancy
  • HIV virus infection, tuberculosis, or other active infection (sepsis, pneumonia, or abscess)
  • diabetes
  • hypertension
  • cardiovascular diseases
  • severe kidney function impairment
  • inflammatory bowel disease or gastric disease
  • history of primary immunodeficiency
  • neoplastic disease within the past 5 years
  • neutrophil count of less than 1500 cells per mm³
  • glycosylated haemoglobin less than 8%
  • partial thromboplastin time 1∙5 times or less the upper limit of normal (ULN); •clinical electrocardiogram changes
  • corrected QT interval greater than 450 ms for men and greater than 470 ms for women
  • secondary thrombocytopenia
  • severe immune-deficiency
  • pregnancy or lactation
  • psychosis
  • osteoporosis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule plus high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

The 2 groups in the trial

  • diammonium glycyrrhizinate enteric-coated capsule + high-dose dexamethasoneExisting treatment, for comparison

    Diammonium glycyrrhizinate enteric-coated capsule orally at a dose of 150mg tid for 1 month, combining with dexamethasone (given orally at a dose of 40 mg qd for 4 days). Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.

    Treatment: dexamethasone and diammonium glycyrrhizinate enteric-coated capsule

  • High-dose dexamethasoneExisting treatment, for comparison

    Dexamethasone orally at a dose of 40 mg qd for 4 days. Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.

    Treatment: dexamethasone

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
High-dose Dexamethasone Plus Diammonium Glycyrrhizinate Enteric-coated Capsule Versus High-dose Dexamethasone in Treatment-naive Primary Immune Thrombocytopenia (ITP): a Multicentre, Randomised, Open-label Trial
Publications
Record updated
26 January 2026